TMX-049

· Teijin America, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TMX-049, covering 2022-08-01 to 2022-08-01. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria [Phase 2]